Enliven Therapeutics, Inc. · NASDAQ:ELVN

Fairmount Funds Management LLC reported a 6.60% stake in Enliven Therapeutics, Inc. (Schedule 13G/A)

Event Dec 31, 2024 · Filed Feb 14, 2025

Fairmount Funds Management LLC reported a 6.60% stake in Enliven Therapeutics, Inc., 3,202,798 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G/A).

Stake
6.60%
Shares
3,202,798
Intent
Passive
What changed
Stake changed
Filed together
4 holders

The filing in full

HolderStakeShares
Fairmount Funds Management LLC6.60%3,202,798
Fairmount Healthcare Fund II L.P.6.60%3,202,798
Peter Harwin6.60%3,202,798
Tomas Kiselak6.60%3,202,798

Source

View original at SEC

Related